Johnson & Johnson (NYSE:JNJ) Shares Acquired by Hendershot Investments Inc.

Hendershot Investments Inc. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 149,736 shares of the company’s stock after purchasing an additional 3,131 shares during the quarter. Johnson & Johnson makes up about 3.0% of Hendershot Investments Inc.’s portfolio, making the stock its 7th biggest holding. Hendershot Investments Inc.’s holdings in Johnson & Johnson were worth $21,655,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Archvest Wealth Advisors Inc. purchased a new position in Johnson & Johnson in the fourth quarter worth approximately $210,000. Apollon Wealth Management LLC grew its stake in shares of Johnson & Johnson by 20.7% in the fourth quarter. Apollon Wealth Management LLC now owns 105,500 shares of the company’s stock valued at $15,257,000 after buying an additional 18,082 shares in the last quarter. Vest Financial LLC raised its holdings in shares of Johnson & Johnson by 10.1% in the 4th quarter. Vest Financial LLC now owns 366,147 shares of the company’s stock valued at $52,952,000 after buying an additional 33,658 shares during the period. SC&H Financial Advisors Inc. boosted its holdings in Johnson & Johnson by 17.0% during the 4th quarter. SC&H Financial Advisors Inc. now owns 1,959 shares of the company’s stock valued at $283,000 after acquiring an additional 285 shares during the period. Finally, Cidel Asset Management Inc. boosted its stake in shares of Johnson & Johnson by 2.8% in the fourth quarter. Cidel Asset Management Inc. now owns 16,338 shares of the company’s stock valued at $2,363,000 after purchasing an additional 440 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Raymond James reduced their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Finally, Bank of America decreased their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Stock Up 1.3 %

Shares of NYSE JNJ opened at $156.18 on Wednesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm’s 50-day moving average is $147.40 and its two-hundred day moving average is $156.04. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The company has a market capitalization of $376.02 billion, a PE ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.29 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.